Aduro offers $7.5M to fuel UC Berkeley's immunotherapy research effort

Berkeley, CA-based Aduro is handing over $7.5 million to UC Berkeley for a 3-year program to investigate a new class of immunotherapeutics called cyclic dinucleotides as well as natural killer (NK) cells. Their work will cover cancer as well as infectious diseases and there's an option to extend the pact by an additional three years. "We're increasingly finding that immune stimulants associated with disease-causing microbes work as cancer therapies, and conversely, that immunotherapies for cancer may have application in fighting infectious disease," said IVRI director David Raulet, a professor and co-chair of the Department of Molecular and Cell Biology. "Bringing infectious disease and cancer researchers together in a synergistic research effort at UC Berkeley and Aduro Biotech is an exciting and unique idea, and could be where the next generation of therapies will come from." Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.